Marshall Wace North America’s CalciMedica CALC Stock Holding History

Marshall Wace North America’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,758	Closed	-$846K	–	1331
2020 Q3	$846K	Buy	+4,758	New	+$992K	0.01%	843

Other funds holding CALC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Marshall Wace North America's CALC Position: Q4 2020 in Review

Marshall Wace North America sold out of CalciMedica (CALC) in Q4 2020, closing a stake of 4,758 shares — an estimated $846K sold.

Marshall Wace North America first reported a position in CALC in Q3 2020 and held it in 1 quarter. The position peaked at $846K in Q3 2020. 33 funds tracked by Wall St. Rank hold CALC as of Q4 2020.

Marshall Wace North America reported no remaining CalciMedica position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 4,758 CalciMedica shares in Q4 2020, an estimated $846K.
Marshall Wace North America first reported a position in CalciMedica in Q3 2020 and held it in 1 quarter.
Marshall Wace North America's CalciMedica position peaked at $846K in Q3 2020.
33 funds tracked by Wall St. Rank held CalciMedica as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.